Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose

Peking University

Status and phase: Unknown; Phase 4

Conditions: Rabies

Treatments: Biological: Rabies vaccine, manufactured by ChengDa

Study type: Interventional

Funder types: Other

Identifiers

NCT01173302

PKUPH-ER-1

Details and patient eligibility

About

This study is to investigate the persistence of rabies Chinese manufactured antibody 1-5 years after the post-exposure prophylaxis with vero cell antirabies vaccine and antibody response to a single booster dose. A total of 160 subjects would be enrolled. These subjects were all administered ChengDa antirabies vaccine from 2005 to 2009. After informed consent is obtained, these subjects would be tested for their antirabies antibody titer and given a single booster dose. Seven and 14 days later, the investigators would re-evaluate the antibody titer.

Enrollment: 160 estimated patients

Sex: All

Ages: 20 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• 20 to 60 years old
• Healthy
• Given ChengDa rabies vaccine
• Good compliance
• Obtained informed consent

Exclusion criteria

• Other than inclusion criteria

Trial design

Primary purpose: Health Services Research

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

160 participants in 1 patient group

Post vaccination

Experimental group

Description:

All the subjects had been vaccinated with antirabies vaccine.

Treatment:

Biological: Rabies vaccine, manufactured by ChengDa